Lung Therapeutics

Lung Therapeutics Acquired by Aileron Therapeutics | Read More

About Us

Improving Outcomes for Lung Disease Patients

Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug candidate, LTI-01, is in clinical development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. The company’s second drug candidate, LTI-03, is in clinical development for Idiopathic Pulmonary Fibrosis (IPF).

LTI-01 for Loculated Pleural Effusion

LTI-01 is a pro-enzyme for the treatment of Loculated Pleural Effusion (LPE).  Pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia.  Pleural effusion is considered loculated when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage.  In a completed ex-US clinical trial in patients, LTI-01 demonstrated preliminary signs of efficacy and no safety concerns.  There are no approved drug therapeutics for the treatment of LPE.  LTI-01 is currently in a dose ranging Phase 2 clinical trial.  The Company has received US and EU Orphan Drug Designations and Fast Track Designation in the US for LTI-01. 

View LTI-01

LTI-03 for Idiopathic Pulmonary Fibrosis

LTI-03 is a novel peptide drug targeting the survival of lung epithelial cells and the inhibition of the negative effects of fibroblast proliferation in Idiopathic Pulmonary Fibrosis patients.   LTI-03 is thought to operate through a novel mechanism and addresses a pathway currently not targeted by other therapeutic candidates. IPF is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function.  IPF typically presents in adults 65 or older and is usually fatal 3-5 years after diagnosis.  LTI-03 is currently in a healthy volunteer Phase 1 clinical study.

View LTI-03